Cloning and Characterization of Phospholipases A2 and Hyaluronidase Genes from the Venom of the Honeybee Apis mellifera carnica (Hymenoptera: Apidae)

Bee venom contains the allergic enzymes phospholipases A2 (PLA2) and hyaluronidase. These enzymes have been extensively studied as therapeutic modalities because of their proven effects in pharmaceutical and clinical applications. The cDNA cloning of PLA2 and hyaluronidase was amplified by RT-PCR from the total RNA of the venom gland of a honeybee (Apis mellifera carnica). The lengths of the PLA2 and hyaluronidase of Apis mellifera ligustica were 504 and 1146bp, respectively. The genes of PLA2 and hyaluronidase shared 90.94% and 96.65% homologies with A. mellifera ligustica and Apis cerana cerana, respectively. Some similar PLA2 and hyaluronidase were also found in the venom of other bee species, We analyzed their sequences and compared them with those of other sources. A notable finding was that the two genes differed from those of A. mellifera ligustica and A. cerana cerana. The positions of the disulfide bonds of PLA2 and hyaluronidase were also completely different from those previously reported. We used the available sequences to construct a phylogenetic tree and discovered that these two genes of A. mellifera carnica belonged to the western honeybee, and was more closely related to that of A. mellifera ligustica than to any other insect

Dedicated JPSS VIIRS Ocean Color Calibration/Validation Cruise

The NOAA/STAR ocean color team is focused on “end-to-end” production of high quality satellite ocean color products. In situ validation of satellite data is essential to produce the high quality, “fit for purpose” remotely sensed ocean color products that are required and expected by all NOAA line offices, as well as by external (both applied and research) users. In addition to serving the needs of its diverse users within the U.S., NOAA has an ever increasing role in supporting the international ocean color community and is actively engaged in the International Ocean-Colour Coordinating Group (IOCCG). The IOCCG, along with the Committee on Earth Observation Satellites (CEOS) Ocean Colour Radiometry Virtual Constellation (OCR-VC), is developing the International Network for Sensor Inter-comparison and Uncertainty assessment for Ocean Color Radiometry (INSITU-OCR). The INSITU-OCR has identified, amongst other issues, the crucial need for sustained in situ observations for product validation, with longterm measurement programs established and maintained beyond any individual mission. Recently, the NOAA/STAR Ocean Color Team has been making in situ validation measurements continually since the launch in fall 2011 of the Visible Infrared Imaging Radiometer Suite (VIIRS) aboard the Suomi National Polar-orbiting Partnership (SNPP) platform, part of the U.S. Joint Polar Satellite System (JPSS) program. NOAA ship time for the purpose of ocean color validation, however, had never been allocated until the cruise described herein. As the institutional lead for this cruise, NOAA/STAR invited external collaborators based on scientific objectives and existing institutional collaborations. The invited collaborators are all acknowledged professionals in the ocean color remote sensing community. Most of the cruise principal investigators (PIs) are also PIs of the VIIRS Ocean Color Calibration and Validation (Cal/Val) team, including groups from Stennis Space Center/Naval Research Laboratory (SSC/NRL) and the University of Southern Mississippi (USM); City College of New York (CCNY); University of Massachusetts Boston (UMB); University of South Florida (USF); University of Miami (U. Miami); and, the National Institute of Standards and Technology (NIST). These Cal/Val PIs participated directly, sent qualified researchers from their labs/groups, or else contributed specific instruments or equipment. Some of the cruise PIs are not part of the NOAA VIIRS Ocean Color Cal/Val team but were chosen to complement and augment the strengths of the Cal/Val team participants. Outside investigator groups included NASA Goddard Space Flight Center (NASA/GSFC), Lamont-Doherty Earth Observatory at Columbia University (LDEO), and the Joint Research Centre of the European Commission (JRC). This report documents the November 2014 cruise off the U.S. East Coast aboard the NOAA Ship Nancy Foster. This cruise was the first dedicated ocean color validation cruise to be supported by the NOAA Office of Marine and Air Operations (OMAO). A second OMAO-supported cruise aboard the Nancy Foster is being planned for late 2015. We at NOAA/STAR are looking forward to continuing dedicated ocean color validation cruises, supported by OMAO on NOAA vessels, on an annual basis in support of JPSS VIIRS on SNPP, J-1, J-2 and other forthcoming satellite ocean color missions from the U.S as well as other countries. We also look forward to working with the U.S. and the international ocean community for improving our understanding of global ocean optical, biological, and biogeochemical properties.JRC.H.1-Water Resource

Screening and identification of Bifidobacterium longum from maternal milk and its domestication of oxygen-domestication

Objective: To screen Bifidobacterium from breast milk and improve its oxygen tolerance under aerobic conditions. Methods: Dilution and spread plate methods were performed to separate and screen Bifidobacterium from breast milk. Their Bifidobacterium identifications were characterized by 16S rDNA sequencing. The oxygen tolerant domestications were conducted through gradual increase of oxygen pressure and alternation of aerobic and anaerobic cultivations. Results: A novel Bifidobacterium strain was isolated from human milk and was identified as Bifidobacterium longum by 16S rDNA sequencing, which was named as MEFZ-2201. The homology between MEFZ-2201 and model strain (accession number in NCBI: ON631733.1) reached 100%. After oxygen tolerant domestication, the highest viable bacteria number of Bifidobacterium longum MEFZ-2201d in aerobic cultivation reached 8.9×109 CFU/mL, which was ten times higher than that of its wild-type strain MEFZ-2201. Whereas, the morphological property and physio-biochemical characteristics of Bifidobacterium longum MEFZ-2201d did not change after oxygen tolerant domestication. The short-chain fatty acid production of domesticated strain Bifidobacterium longum MEFZ-2201d was also significantly higher than that of its wild-type strain even under anaerobic conditions. Conclusion: A novel Bifidobacterium longum strain MEFZ-2201 was isolated from breast milk. The viable bacterium number of its domesticated strain MEFZ-2201d was significantly increased under aerobic conditions, indicating that it would be a potential probiotic strain for further development and utilization

LQTS Gene LOVD Database

The Long QT Syndrome (LQTS) is a group of genetically heterogeneous disorders that predisposes young individuals to ventricular arrhythmias and sudden death. LQTS is mainly caused by mutations in genes encoding subunits of cardiac ion channels (KCNQ1, KCNH2, SCN5A, KCNE1, and KCNE2). Many other genes involved in LQTS have been described recently (KCNJ2, AKAP9, ANK2, CACNA1C, SCNA4B, SNTA1, and CAV3). We created an online database (http://www.genomed.org/LOVD/introduction.html) that provides information on variants in LQTS-associated genes. As of February 2010, the database contains 1738 unique variants in 12 genes. A total of 950 variants are considered pathogenic, 265 are possible pathogenic, 131 are unknown/unclassified, and 292 have no known pathogenicity. In addition to these mutations collected from published literature, we also submitted information on gene variants, including one possible novel pathogenic mutation in the KCNH2 splice site found in ten Chinese families with documented arrhythmias. The remote user is able to search the data and is encouraged to submit new mutations into the database. The LQTS database will become a powerful tool for both researchers and clinicians. © 2010 Wiley-Liss, Inc

Prognostic genes related to mitochondrial dynamics and mitophagy in diffuse large B-cell lymphoma are identified and validated using an integrated analysis of bulk and single-cell RNA sequencing

BackgroundWhile the link between mitochondrial homeostasis, specifically dynamics and mitophagy, and the progression of diffuse large B-cell lymphoma (DLBCL) has been suggested, their prognostic significance and functional networks remain unclear. This study aimed to investigate the role of mitochondrial dynamics-related genes (MDRGs) in DLBCL patient outcomes.MethodsCandidate MDGRs were identified via Weighted Gene Co-expression Network Analysis (WGCNA) and differential expression analysis using public RNA-seq data. A prognostic signature was established via LASSO-Cox regression, followed by proportional hazards assumption validation. Functional pathways, regulatory networks (including miR-1252-5p/NEAT1), and a risk-scoring model were analyzed. Model assessment included nomograms, immune cell infiltration, m6A regulator, and pharmacogenomics. Single-cell mapping was employed to characterize B-cell differentiation and spatial gene expression. Finally, the findings were validated using RT-qPCR on clinical samples.ResultsSix lysosomal-enriched genes (TCF7, CEBPA, BBC3, GALR3, BMP8B, and BAALC) were identified as independent prognostic indicators. A composite model integrating our risk score and clinical parameters showed superior predictive accuracy (AUC > 0.8). High-risk DLBCL was characterized by altered M0 macrophage infiltration, YTHDC1-mediated m6A dysregulation, and dihydrotestosterone sensitivity. Single-cell analysis revealed an association between stage-specific B-cell differentiation and gene expression gradients. RT-qPCR confirmed the upregulation of CEBPA, BBC3, GALR3, BMP8B, and BAALC in DLBCL clinical samples.ConclusionTCF7, CEBPA, BBC3, GALR3, BMP8B, and BAALC were identified as novel lysosomal pathway-enriched prognostic genes in DLBCL. Our validated composite model demonstrated strong predictive power. These findings establish an association between high-risk disease and specific tumor microenvironment alterations (M0 macrophages), epitranscriptomic dysregulation (m6A), and therapeutic vulnerabilities, providing valuable insights for refining prognosis and advancing targeted therapies for DLBCL